Biomarkers, Abdominal Muscle, and Frailty in CKD

NCT07854275 | Completed

• 1 other identifier: Samsun-PMR-DRHENY-02
• Study Type: observational
• Target: 88
• Locations: 1 country
• Sites: 1

Brief Summary

In chronic kidney disease (CKD), inflammation and oxidative stress are important processes that may be associated with the development of muscle loss and frailty. The aim of this study is to investigate the relationships between serum MCP-1, total antioxidant status (TAS), and total oxidant status (TOS)-markers of inflammation and oxidative stress-and abdominal muscle thickness and frailty, as assessed by ultrasound, in stage 3-5 CKD patients not receiving dialysis. In addition, the study aims to assess participants' physical performance, kinesiophobia, and quality of life and to examine these characteristics according to CKD stages.

Conditions

Chronic Kidney Disease; Abdominal Muscles/Ultrasonography; Frailty

Keywords

abdominal muscle; chronic kidney disease; monocyte chemoattractant protein-1; total antioxidant status; total oxidant status

Outcome Measures

Primary Outcomes (5)

• Ultrasonography measurements

  abdominal muscles

  20 week

• Frailty

  FRAIL scale

  20 weeks

• Frailty 2

  clinic frailty scale

  20 weeks

• total antioxidant status

  total antioxidant status

  20 weeks

• total oxidant status

  total oxidant status

  20 week

Secondary Outcomes (1)

• kinesiophobia

  20 week

Study Arms (3)

stage 3

chronic kidney disease stage 3

Other: total antioxidant status; Other: total oxidant status; Other: monocyte chemotactic protein-1; Other: ultrasonography muscle; Other: FRAIL scale; Other: clinical frailty scale; Other: tampa scale

stage 4

chronic kidney disease stage 4

Other: total antioxidant status; Other: total oxidant status; Other: monocyte chemotactic protein-1; Other: ultrasonography muscle; Other: FRAIL scale; Other: clinical frailty scale; Other: tampa scale

stage 5

chronic kidney disease stage 5

Other: total antioxidant status; Other: total oxidant status; Other: monocyte chemotactic protein-1; Other: ultrasonography muscle; Other: FRAIL scale; Other: clinical frailty scale; Other: tampa scale

Interventions

total antioxidant status OTHER

total antioxidant status

stage 3; stage 4; stage 5

total oxidant status OTHER

total oxidant status

stage 3; stage 4; stage 5

monocyte chemotactic protein-1 OTHER

monocyte chemotactic protein-1

stage 3; stage 4; stage 5

ultrasonography muscle OTHER

abdominal muscles

stage 3; stage 4; stage 5

FRAIL scale OTHER

frailty

stage 3; stage 4; stage 5

clinical frailty scale OTHER

frailty

stage 3; stage 4; stage 5

tampa scale OTHER

kinesiophobia

stage 3; stage 4; stage 5

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

18-70 years stage 3-5 CKD

You may qualify if:

• Be between the ages of 18 and 70; have been diagnosed with stage 3, 4, or 5 chronic kidney disease (CKD) for at least 6 months; have been receiving stable medical treatment for the past 6 months; be in a clinically stable condition; have no cognitive impairment; be literate; and have no vision or hearing problems that would prevent the administration of the scales

You may not qualify if:

• Patients undergoing dialysis; those with acute infection, malignancy, uncontrolled hypertension, severe heart failure, a history of neurological disease (stroke, cerebral hemorrhage), or severe anemia (Hb \< 7); pregnant women; patients with immunodeficiency; those taking steroids; and patients with chronic inflammatory diseases.

Sponsors & Collaborators

• Ankara City Hospital Bilkent: lead

Study Sites (1)

Samsun Training and Research hospital

Samsun, Turkey (Türkiye)

Location

Related Publications (7)

• Yousefzadeh MJ, Schafer MJ, Noren Hooten N, Atkinson EJ, Evans MK, Baker DJ, Quarles EK, Robbins PD, Ladiges WC, LeBrasseur NK, Niedernhofer LJ. Circulating levels of monocyte chemoattractant protein-1 as a potential measure of biological age in mice and frailty in humans. Aging Cell. 2018 Apr;17(2):e12706. doi: 10.1111/acel.12706. Epub 2017 Dec 31.

  PMID: 29290100 BACKGROUND

• Beyer I, Njemini R, Bautmans I, Demanet C, Bergmann P, Mets T. Inflammation-related muscle weakness and fatigue in geriatric patients. Exp Gerontol. 2012 Jan;47(1):52-9. doi: 10.1016/j.exger.2011.10.005. Epub 2011 Oct 18.

  PMID: 22032874 BACKGROUND

• Schettini IVG, Faria DV, Nogueira LS, Otoni A, Silva ACSE, Rios DRA. Renin angiotensin system molecules and chemokine (C-C motif) ligand 2 (CCL2) in chronic kidney disease patients. J Bras Nefrol. 2022 Jan-Mar;44(1):19-25. doi: 10.1590/2175-8239-JBN-2021-0030.

  PMID: 34251390 BACKGROUND

• Watanabe H, Enoki Y, Maruyama T. Sarcopenia in Chronic Kidney Disease: Factors, Mechanisms, and Therapeutic Interventions. Biol Pharm Bull. 2019;42(9):1437-1445. doi: 10.1248/bpb.b19-00513.

  PMID: 31474705 BACKGROUND

• Chao CT, Kovesdy CP, Merchant RA. Sarcopenia, sarcopenic obesity, and frailty in individuals with chronic kidney disease: a comprehensive review. Kidney Res Clin Pract. 2026 Mar;45(2):174-188. doi: 10.23876/j.krcp.24.207. Epub 2025 Jan 21.

  PMID: 39973319 BACKGROUND

• Wang XH, Mitch WE. Mechanisms of muscle wasting in chronic kidney disease. Nat Rev Nephrol. 2014 Sep;10(9):504-16. doi: 10.1038/nrneph.2014.112. Epub 2014 Jul 1.

  PMID: 24981816 BACKGROUND

• Bello AK, Alrukhaimi M, Ashuntantang GE, Basnet S, Rotter RC, Douthat WG, Kazancioglu R, Kottgen A, Nangaku M, Powe NR, White SL, Wheeler DC, Moe O. Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action. Kidney Int Suppl (2011). 2017 Oct;7(2):122-129. doi: 10.1016/j.kisu.2017.07.007. Epub 2017 Sep 20.

  PMID: 30675426 BACKGROUND

MeSH Terms

Conditions

Renal Insufficiency, Chronic; Frailty

Interventions

Chemokine CCL2

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Monocyte Chemoattractant Proteins; Chemokines, CC; Chemokines; Cytokines; Intercellular Signaling Peptides and Proteins; Peptides; Amino Acids, Peptides, and Proteins; Proteins; Chemotactic Factors; Biological Factors; Inflammation Mediators

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: specialist medical doctor

Study Record Dates

• First Submitted: September 28, 2026
• First Posted: October 2, 2026
• Study Start: January 15, 2025
• Primary Completion: May 15, 2025
• Study Completion: August 1, 2026
• Last Updated: October 2, 2026

Record last verified: 2026-09

Locations

TU (1)